<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306656</url>
  </required_header>
  <id_info>
    <org_study_id>AAAF1797</org_study_id>
    <secondary_id>R01DK084986-05</secondary_id>
    <nct_id>NCT01306656</nct_id>
  </id_info>
  <brief_title>Vitamin D Repletion in Primary Hyperparathyroidism</brief_title>
  <official_title>Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the effect of 2 treatment regimens that contain vitamin D in a
      six-month treatment trial of patients with PHPT who are vitamin D deficient. Patients will be
      assigned randomly to one of 2 regimens, and will be followed with tests of their blood, urine
      and bones. This study should provide important information on the effect of vitamin D therapy
      in patients with PHPT. In addition, data from this study will guide physicians as to how best
      to treat their patients who have PHPT and vitamin D deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary hyperparathyroidism (PHPT) is a common disease in which the parathyroid glands
      produce excessive amounts of parathyroid hormone (PTH), which regulates calcium levels. In
      primary hyperparathyroidism, high levels of PTH remove too much calcium from bones and
      deposit the excess calcium in the blood, which is then filtered into the urine by the
      kidneys. Bone health is threatened by the excess calcium loss which weakens the structure of
      the bones.

      Many patients with primary hyperparathyroidism also have low vitamin D (25OHD) levels which
      is thought to further impair bone health. Recent medical guidelines recommend treating
      patients with primary hyperparathyroidism who have low vitamin D levels with oral vitamin D
      but the optimal vitamin D dose and rate of repletion is unclear. It is, therefore, important
      to determine if replenishing Vitamin D will improve bone health in primary
      hyperparathyroidism, and if so, to assess the impact of the rate of vitamin D repletion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Active arm:
Month 1: 20,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.
Months 2-6: 10,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.
Placebo arm:
Month 1: Placebo once a week plus daily multivitamin with 400 IU vitamin D.
Months 2-6: Placebo every week plus daily multivitamin with 400 IU vitamin D.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patient, investigator and study team will be blinded to study arm ramdomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Parathyroid Hormone (PTH) Level</measure>
    <time_frame>6 months</time_frame>
    <description>This is designed to measure how many participants will achieve PTH &gt; 65 pg/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Areal Bone Mineral Density of the Lumbar Spine</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by dual-energy x-ray absorptiometry (DEXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular Bone Density at the Forearm</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by high resolution peripheral quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Calcium Level</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>This is designed to measure how the study treatment will affect urinary calcium level over time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus a multivitamin with 400 IU vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10,000 IU Vitamin D3</intervention_name>
    <description>Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Cholecalciferol-D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Month 1: Placebo once a week
Months 2-6: Placebo once a week</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Placebo pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Daily multivitamin with 400 IU vitamin D.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed PHPT, defined by an elevated serum calcium level (we will not study
             normocalcemic PHPT) with elevated or inappropriately normal PTH levels.

          -  Vitamin D3 less than 30 ng/ml

        Exclusion Criteria:

          -  Patients with familial hyperparathyroid syndromes

          -  Current or past use of the following medications: bisphosphonate within past 2 years,
             use of lithium or thiazide diuretics, current use of cinacalcet, use of aluminum
             containing medications, cimetidine, colestipol, or orlistat

          -  Malignancy, except cured basal or squamous cell skin carcinoma or other cured cancers
             that are at least five years free from recurrence

          -  History or current diagnosis of certain medical diseases (including sarcoidosis,
             active infectious granulomatous disease, HIV/AIDS, chronic kidney disease (serum
             creatinine &gt; 1.5 mg/dL), liver disease; GI diseases known to affect calcium
             metabolism; secondary hyperparathyroidism);

          -  We will also exclude patients with calcium above 11.5 mg/dL, urine calcium above 350
             mg/day, and active nephrolithiasis because vitamin D repletion could potentially
             exacerbate hypercalcemia or hypercalciuria

          -  Other exclusions include protected individuals (institutionalized), prisoners, and any
             other prospective participant who might not be able to give voluntary informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shonni J Silverberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <results_first_submitted>May 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <disposition_first_submitted>March 5, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 15, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 19, 2018</disposition_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Shonni J. Silverberg</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Endocrinology</keyword>
  <keyword>Metabolic Bone Disease</keyword>
  <keyword>Primary Hyperparathyroidism</keyword>
  <keyword>PHPT</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Hyper-calcemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 2, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT01306656/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>10,000 IU Vitamin D3 + Multivitamin</title>
          <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
10,000 IU Vitamin D3: Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Multivitamin</title>
          <description>Placebo plus a multivitamin with 400 IU vitamin D
Placebo: Month 1: Placebo once a week
Months 2-6: Placebo once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10,000 IU Vitamin D3 + Multivitamin</title>
          <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
10,000 IU Vitamin D3: Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Multivitamin</title>
          <description>Placebo plus a multivitamin with 400 IU vitamin D
Placebo: Month 1: Placebo once a week
Months 2-6: Placebo once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Parathyroid Hormone (PTH) Level</title>
        <description>This is designed to measure how many participants will achieve PTH &gt; 65 pg/mL.</description>
        <time_frame>6 months</time_frame>
        <population>Study enrollment did not reach the required number of subjects; the analysis results would not have been reliable or have enough statistical power. Therefore, samples were not processed and data was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>10,000 IU Vitamin D3 + Multivitamin</title>
            <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
10,000 IU Vitamin D3: Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Multivitamin</title>
            <description>Placebo plus a multivitamin with 400 IU vitamin D
Placebo: Month 1: Placebo once a week
Months 2-6: Placebo once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Parathyroid Hormone (PTH) Level</title>
          <description>This is designed to measure how many participants will achieve PTH &gt; 65 pg/mL.</description>
          <population>Study enrollment did not reach the required number of subjects; the analysis results would not have been reliable or have enough statistical power. Therefore, samples were not processed and data was not available for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Areal Bone Mineral Density of the Lumbar Spine</title>
        <description>Measured by dual-energy x-ray absorptiometry (DEXA) scan</description>
        <time_frame>6 months</time_frame>
        <population>Study enrollment did not reach the required number of subjects; the analysis results are not reliable or have enough statistical power.</population>
        <group_list>
          <group group_id="O1">
            <title>10,000 IU Vitamin D3 + Multivitamin</title>
            <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
10,000 IU Vitamin D3: Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Multivitamin</title>
            <description>Placebo plus a multivitamin with 400 IU vitamin D
Placebo: Month 1: Placebo once a week
Months 2-6: Placebo once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
          </group>
        </group_list>
        <measure>
          <title>Areal Bone Mineral Density of the Lumbar Spine</title>
          <description>Measured by dual-energy x-ray absorptiometry (DEXA) scan</description>
          <population>Study enrollment did not reach the required number of subjects; the analysis results are not reliable or have enough statistical power.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.98777" spread="1.662643"/>
                    <measurement group_id="O2" value="1.442861" spread="4.376592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trabecular Bone Density at the Forearm</title>
        <description>Measured by high resolution peripheral quantitative computed tomography</description>
        <time_frame>6 months</time_frame>
        <population>Study enrollment did not reach the required number of subjects; the analysis results are not reliable nor have enough statistical power.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
10,000 IU Vitamin D3: Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Placebo plus a multivitamin with 400 IU vitamin D
Placebo: Month 1: Placebo once a week
Months 2-6: Placebo once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
          </group>
        </group_list>
        <measure>
          <title>Trabecular Bone Density at the Forearm</title>
          <description>Measured by high resolution peripheral quantitative computed tomography</description>
          <population>Study enrollment did not reach the required number of subjects; the analysis results are not reliable nor have enough statistical power.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00345" spread="3.912386"/>
                    <measurement group_id="O2" value="-2.59816" spread="0.583978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Calcium Level</title>
        <description>This is designed to measure how the study treatment will affect urinary calcium level over time.</description>
        <time_frame>1 month, 3 months, 6 months</time_frame>
        <population>Data is provided for 6 out of the 7 participants in Group 1 due to that 1 participant became lost to follow-up and did not complete lab testing at Month 3 and 6.</population>
        <group_list>
          <group group_id="O1">
            <title>10,000 IU Vitamin D3 + Multivitamin</title>
            <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
10,000 IU Vitamin D3: Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Multivitamin</title>
            <description>Placebo plus a multivitamin with 400 IU vitamin D
Placebo: Month 1: Placebo once a week
Months 2-6: Placebo once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Calcium Level</title>
          <description>This is designed to measure how the study treatment will affect urinary calcium level over time.</description>
          <population>Data is provided for 6 out of the 7 participants in Group 1 due to that 1 participant became lost to follow-up and did not complete lab testing at Month 3 and 6.</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.67" lower_limit="9" upper_limit="453"/>
                    <measurement group_id="O2" value="154" lower_limit="76" upper_limit="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.67" lower_limit="6" upper_limit="282"/>
                    <measurement group_id="O2" value="115.5" lower_limit="51" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.17" lower_limit="12" upper_limit="387"/>
                    <measurement group_id="O2" value="50.5" lower_limit="30" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Definitions do not differ from those of the ClinicalTrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
10,000 IU Vitamin D3: Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Placebo plus a multivitamin with 400 IU vitamin D
Placebo: Month 1: Placebo once a week
Months 2-6: Placebo once a week
Vitamin D: Daily multivitamin with 400 IU vitamin D.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Constipation for 5 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Urinary infection - E. Coli</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <description>right nephrolithiasis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study enrollment did not reach the required number of subjects; the analysis results would not have been reliable or have enough statistical power. Therefore, samples were not processed and data was not analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shonni Silverberg, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-6291</phone>
      <email>sjs7@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

